<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04938102</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00147450</org_study_id>
    <nct_id>NCT04938102</nct_id>
  </id_info>
  <brief_title>Role of EndoFLIP in the Diagnostic Paradigm of Esophagogastric Junction Outflow Obstruction</brief_title>
  <acronym>EndoFLIP</acronym>
  <official_title>Role of EndoFLIP in the Diagnostic Paradigm of Esophagogastric Junction Outflow Obstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this project is to identify if EndoFLIP can categorize and change the diagnosis in&#xD;
      patients with EGJOO and if categorization with EndoFLIP can predict the response to treatment&#xD;
      with botulinum toxin at 12 weeks post procedure. Our hypothesis is that there will be a&#xD;
      larger difference in proportion of symptom resolution between the control and treatments&#xD;
      groups in the abnormal DI category than in the normal DI category.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Esophagogastric Outflow Obstruction (EGJOO) is a newer diagnosis in which some patients'&#xD;
      symptoms resolve spontaneously or with conservative treatment, while others require treatment&#xD;
      with botulinum toxin injected into the lower esophageal sphincter. Currently, there is no way&#xD;
      to distinguish these two groups of patients upon diagnosis. EndoFLIP (endolumenal functional&#xD;
      lumen imaging probe) is a new technology that can measure the distensibility index (DI) of&#xD;
      the lower esophageal sphincter. Data has suggested that normal and abnormal DI measurements&#xD;
      can categorize these patients and guide treatment course (1). Our study looks to confirm this&#xD;
      finding.&#xD;
&#xD;
      1. Elsbernd et al. Clinical characteristics and treatment response of esophagogastric&#xD;
      junction outflow obstruction. Gastroenterology 2019;156(6):S-1017.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptom Resolution</measure>
    <time_frame>12 weeks.</time_frame>
    <description>The primary endpoint is the proportion of patients with complete symptom resolution at 12 weeks (Eckardt score &lt; 3) post procedure in each group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in symptom score</measure>
    <time_frame>12 weeks.</time_frame>
    <description>The secondary endpoint is the percent change in symptom score at 12 weeks in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean symptom scores</measure>
    <time_frame>12 weeks.</time_frame>
    <description>The secondary endpoint is the change in mean symptom score in each group at 12 weeks.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Esophagogastric Junction Disorder</condition>
  <arm_group>
    <arm_group_label>Abnormal DI - Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients' whose distensibility index is measured &lt;2.8 will receive no intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abnormal DI - Botox</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients' whose distensibility index is measured &lt;2.8 will be injected with 100 units of botulinum toxin in the lower esophageal sphincter (25 units in each quadrant).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal DI - Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients' whose distensibility index is measured &gt;2.8 will receive no intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal DI - Botox</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients' whose distensibility index is measured &gt;2.8 will be injected with 100 units of botulinum toxin in the lower esophageal sphincter (25 units in each quadrant).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A Injection [Botox]</intervention_name>
    <description>Injection of 100 units of botulinum toxin into the lower esophageal sphincter (25 units in each quadrant).</description>
    <arm_group_label>Abnormal DI - Botox</arm_group_label>
    <arm_group_label>Normal DI - Botox</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosed with esophagogastric junction outflow obstruction by high resolution&#xD;
             manometry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous upper gastrointestinal surgery&#xD;
&#xD;
          -  significant medical co-morbidities&#xD;
&#xD;
          -  eosinophilic esophagitis&#xD;
&#xD;
          -  severe reflux esophagitis (LA-classification C or D)&#xD;
&#xD;
          -  large hiatal hernia&#xD;
&#xD;
          -  patients experiencing significant weight loss suspicious for malignancy&#xD;
&#xD;
          -  Vulnerable populations such as cognitively or decisionally impaired individuals,&#xD;
             children, pregnant women, prisoners, and students or employees of the University of&#xD;
             Kansas Health System or Medical Center&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reza Hejazi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tabitha M Norbury</last_name>
    <phone>417-684-7524</phone>
    <email>tnorbury@kumc.edu</email>
  </overall_contact>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>June 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2021</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Reza Hejazi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

